Dear Gentle Reader,

This November is a watershed month for a few companies – Rx being one of them. Alongside Emirates, we celebrate our 25^th Anniversary this November – having started the company on Black Friday (Friday 13^th November 2000). I will readily admit that compared with Emirates, our internal team and global reach is miniscule to say the least; but that said, we are very proud of the importance of the work we do and that many of our projects have helped drive significant improvements in healthcare. Another company reaching a substantial milestone is Gemporia (21 years old); ethically sourced gemstones with a website that I probably peruse all too often. On a (fractionally) more literary front, DC Comics celebrates its 90^th anniversary this month.

Again we can’t compete with either longevity or size of readership, but it’s not an issue for Rx. Our work has the ability to indirectly save lives and heal people, as well as educate and entertain. And we believe this outshines them all.

‍

Yours truly, 

Ruth

25 Years of Turning Science into Story

This November marks 25 years of Rx Communications — a milestone that reflects not only longevity, but evolution. From our beginnings in November 2000 to today’s global network of scientific communicators, strategists, and project managers, one thing has remained constant: our belief that evidence alone is not enough.

For a quarter of a century, we’ve helped pharmaceutical and biotech partners bring data to life, bridging science and storytelling, and transforming research into meaningful impact. As we celebrate this milestone, we’re looking ahead to how the next era of MedComms will be defined: by insight, collaboration, and innovation.

Turning Data into Dialogue: The MedComms Advantage

In 25 years of medical communication, one truth has stood the test of time: clinical data only drives progress when it’s understood, trusted, and used. The MedComms landscape has evolved, but our role remains the same: to translate complexity into clarity.

At Rx Communications, our team works at the intersection of science and communication, helping clients turn evidence into informed action. We:

• Bridge the gap between evidence and action, transforming data into compelling, context-rich narratives that inspire confidence and change.
• Tailor communications for every audience, from regulators and HCPs to patients and internal stakeholders, ensuring messages are relevant, credible, and accessible.
• Balance rigour with results, maintaining scientific integrity while meeting timelines, compliance standards, and engagement goals.

Our work ensures that the science doesn’t just speak, it resonates.

Best Practices: Writing for Impact

As communication channels diversify, so too must our approach to sharing science. Writing for impact today means crafting content that informs, engages, and endures.

Here are some of the tools and techniques shaping the next 25 years of impactful communication:

• Visual abstracts and data visualisation: transforming complex data into accessible, shareable formats that increase reach and understanding.
• Plain language summaries (PLS): promoting transparency and inclusion by helping patients and the public access and interpret clinical research.
• Digital-first formats: from interactive PDFs and modular content to animations, enabling consistent and engaging delivery across channels.
• Strategic publication planning: aligning communications with study milestones, congress cycles, and broader brand objectives to maximise visibility and value.

At Rx, we’ve seen the power of communication evolve, from printed abstracts to interactive ecosystems. What remains constant is our mission: to ensure that every piece of scientific writing contributes to progress, understanding, and better patient outcomes.

Think you could be making a bigger impact? 

We’ve spent 25 years working with teams that value clarity, evidence and impact. So as we look forward to the next 25… we’d love you to join us. 

Perhaps you’re reviewing your publication pipeline, planning for 2026, or exploring new digital communication formats?

Let’s talk about how we can help: Get in touch

Notable News

FDA Approves First Treatment for Rare Mitochondrial Disorder

The FDA has approved Kygevvi (doxecitine and doxribtimine) — the first treatment for thymidine kinase 2 deficiency (TK2d), in adults and paediatric patients. TK2d is a rare inherited mitochondrial disease affecting muscle function and respiration. In clinical data, Kygevvi reduced mortality rates from 36% to 4% compared with untreated patients and nearly doubled average survival time to 9.6 years. This breakthrough therapy marks a significant step forward for patients with mitochondrial depletion syndromes, a group of conditions often underdiagnosed and historically lacking treatment options. [Link]

Retinal Implant Restores Vision in Advanced AMD

A new wireless retinal implant, the PRIMA system, has shown promise in restoring central vision for people with geographic atrophy, an advanced form of age-related macular degeneration. In a recent NEJM study, over 80% of participants regained the ability to read letters and words, with some improving by up to 12 lines on a standard eye chart. The implant is a very small chip, implanted into the back of the eye and paired with special glasses. The chip transmits images to the glasses, allowing the patient to see in real time. [Link]

First Alzheimer’s Pill for Genetically At-Risk Patients Shows Promise

A new oral drug, valiltramiprosate (ALZ-801), has shown encouraging Phase 3 trial results in people carrying two copies of the APOE4 gene variant, which confers the highest genetic risk for Alzheimer’s disease. In 325 participants with mild cognitive impairment or early Alzheimer’s, the drug slowed brain atrophy and neurodegeneration, suggesting protection of neurons and improved cognitive function. Unlike current antibody infusions, ALZ-801 is designed to act earlier in the disease process, blocking toxic amyloid formation before plaques develop, offering a potentially safer, more convenient treatment option for this high-risk group. [Link]

Check Out Our Latest Blog Posts  

Too Young For Bowel Cancer? Think Again Read more.

BRCA-Related Breast Cancer: Why Timing Could Be the Key to Better... Read more.

Skin Cancer Awareness Is Higher than Ever — So Why Are Tanning Beds and Sun Bathing Still a Thing? Read more

10 Actions That May Help Prevent Alzheimer’s — According to Science. Read more

Strategic Publication Plan with Your MedComms Partner: 10 Essentials for Success. Read more

Critical Appraisal: Amazed or Dismayed? Read more

‍

Visit the blog